Nitric Oxide and sex differences in cardiac repair
Nitric Oxide and sex differences in cardiac repair
批准号:
9331951
负责人:
Joshua M Hare
金额:
$40.61万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-17 至 2021-02-28
关键词:
AffectAgonistAlcohol dehydrogenaseAngiotensin IIAntioxidantsAttentionBuffersCardiacCardiac MyocytesCardiovascular AbnormalitiesCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCause of DeathClinicalComplicationCysteineDataDevelopmentDisease OutcomeEnzymesEquilibriumEstrogen ReceptorsExhibitsFemaleGenderGlutathione DisulfideHeartHeart DiseasesHormonalInjuryLeadMediatingMenopauseModelingMusMyocardial InfarctionMyocardial dysfunctionNitric OxideOutcomeOxidation-ReductionOxidative StressOxidoreductasePPAR gammaPathologyPathway interactionsPeroxisome Proliferator-Activated ReceptorsPhenotypePhosphorylationPhysiologicalPlayPre-EclampsiaPregnancyPregnancy ComplicationsPremenopauseProcessProductionProtein SProteinsProteinuriaReactive Oxygen SpeciesRegulationRoleS-NitrosoglutathioneSex CharacteristicsSignal PathwaySignal TransductionSignaling ProteinSiteSourceStressSulfhydryl CompoundsSyndromeSystemTXN geneTestingTherapeuticTreatment EfficacyVascular blood supplyWomanascorbatebasecalmodulin-dependent protein kinase IIcardiac repaircardiovascular healtheffective therapyexperiencegender differenceimprovedinsightmalematernal hypertensionmenmortalitynoveloxidative damagepregnantprogramsprotective effectresponsesexstressor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary: This program will have a major impact in the treatment of cardiovascular disease (CVD),
the leading cause of death in men and women globally. Premenopausal women are less susceptible to heart
disease than men, and this protection is lost after menopause. Emerging data suggest that the interplay
between nitric oxide (NO) and reactive oxygen species (ROS), the nitroso-redox balance, plays a critical role in
this sex-related cardioprotection. Elucidating the mechanisms underlying these gender differences is critical for
development of effective therapies. S-nitrosylation (S-NO) of cysteine thiols is a major signaling pathway
through which NO exerts its broad regulatory actions. It is increasingly appreciated that the underlying
signaling fate of NO ultimately depends upon an intracellular state of nitroso-redox balance; such that
excessive production of ROS can disrupt physiological S-NO and that CVD may reflect dysregulated protein S-
NO. We have shown that the nitroso/redox balance is an important regulator of CV health and disease. Female
mice have 65% more S-nitrosylated proteins in the heart6 and physiologically regulate this elevated level of S-
NO with increased activity of S-nitrosoglutathione (GSNO) reductase (GSNOR), an enzyme that promotes
protein denitrosylation. We previously showed that male mice lacking S-nitrosoglutathione (GSNO) reductase,
an enzyme that governs S-NO levels by promoting protein denitrosylation (GSNOR−⁄− mice) exhibit improved
survival after myocardial infarction (MI). Furthermore, pregnant GSNOR−/− mice exhibit all of the clinical
features of a major complication in pregnancy, preeclampsia (PE), including maternal hypertension, proteinuria
and abnormal CV adaptation. Poor outcome in the GSNOR−/− females may be due to oxidative stress, as our
preliminary data shows that cardiomyocytes (CMs) from GSNOR−/− females generate more ROS as compared
to CMs from control females and GSNOR−/− males. Therefore, the state of increased S-NO can lead to an
adverse milieu if accompanied by oxidative stress and we have uncovered a sex-associated relationship
between cardiac pathology and intra-cellular nitroso-redox imbalance, which is dependent on NO and ROS
production and S-NO formation and denitrosylation. Our central hypothesis is that the absence of GSNOR
produces a sex-specific, antioxidant milieu in the setting of normal ROS levels (i.e., males) but one of
nitrosative/oxidative stress when ROS is elevated (i.e., females). Our proposal aims to identify the fundamental
mechanisms underlying this dichotomy. The specific aims are to test the hypotheses that 1) differences in
nitroso-redox protein signaling determine sex-specific responses to CV stress; 2) nitroso-redox imbalance in
cadiomyocytes during pregnancy underlies pregnancy-related CVD; and 3) GSNOR produces sex-specific
changes in the S-nitrosylation of proteins that alter CV function. Together these aims will provide novel insights
into nitroso-redox regulation of cardiac function in response to physiologic and pathophysiologic stressors and
have significant implications for the treatment of CVD in men and women.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
-
批准号:10721103
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2023
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10274833
-
项目类别:
-
资助金额:$117.83万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10295008
-
项目类别:
-
资助金额:$65.79万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac
-
批准号:10090766
-
项目类别:
-
资助金额:$101.72万
-
财政年份:2019
-
负责人:Joshua M Hare
-
依托单位:
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
-
批准号:9922198
-
项目类别:
-
资助金额:$197.43万
-
财政年份:2018
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9925908
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9348026
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Pathways to Cardiovascular Therapeutics
-
批准号:8986055
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2015
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8288406
-
项目类别:
-
资助金额:$71.55万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8448599
-
项目类别:
-
资助金额:$65.07万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8628873
-
项目类别:
-
资助金额:$66.46万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8065336
-
项目类别:
-
资助金额:$64.43万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8208055
-
项目类别:
-
资助金额:$62.55万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8502552
-
项目类别:
-
资助金额:$62.02万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8411600
-
项目类别:
-
资助金额:$64.93万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8300026
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8880266
-
项目类别:
-
资助金额:$60.41万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8205725
-
项目类别:
-
资助金额:$63.95万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8589378
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8680353
-
项目类别:
-
资助金额:$63.89万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: